Radiation plus immunotherapy may make inoperable liver cancer operable
NCT ID NCT07305428
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study is testing whether combining stereotactic body radiation therapy (SBRT) with immunotherapy can shrink liver tumors that are too large or widespread to be surgically removed. The goal is to make these tumors operable, giving patients a chance at curative surgery. The study will enroll 30 adults with unresectable hepatocellular carcinoma (HCC) and will measure how many patients are successfully downstaged to become surgical candidates.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Stereotactic body radiation therapy (SBRT) followed by immunotherapy drugs
- What this could lead to
- If successful, this approach could allow some patients with inoperable liver cancer to become candidates for surgery, potentially improving their long-term survival.
- What could go wrong
- This is a very early pilot study with only 30 participants. It is not yet known if the combination will be effective or safe, and immunotherapy can cause serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC - HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Queen Mary Hospital
RECRUITINGHong Kong, Hong Kong
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo shrink liver tumors?
- Can an IDO1 inhibitor boost immunotherapy against liver cancer?
- AI takes on liver cancer: could a computer help pick the right immunotherapy?
- Ancient herbal mix could boost liver health in advanced cancer
- Double immune attack: new drug combo takes on advanced liver cancer
- Immunotherapy combo tested against untreatable liver cancer